enGene Therapeutics Inc.
Tremor tracks 1 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- Announced layoffs or restructuringSince Jun 18, 2026+2.9
- A key executive is leavingSince Jun 15, 2026+2.8
- Announced layoffs or restructuringSince Jun 15, 2026+2.8
Trials
Key executives leaving
From the last 12 months of the company's SEC reports.
Jun 15, 2026
“Resignation of Chief Medical Officer On June 13, 2026, Dr.”
Read the filing ↗
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 1 purchase
- Grossman WilliamInterim Chief Medical Officer · Sep 22, 2026Bought 5,102 sharesabout $10 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Sep 8, 2026
- Shared quarterly resultsNews report (8-K)Sep 8, 2026
- Other newsNews report (8-K)Aug 11, 2026
- Shared information with investorsNews report (8-K)Jul 17, 2026
- An executive or board member joined or left; Shared information with investorsNews report (8-K)Jul 16, 2026
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.